Trial Profile
A Randomised, Open-label, Cross-over Study of Flutiform® BAI and Flutiform® pMDI Devices in Adolescents and Adult Subjects With Persistent Asthma or Chronic Obstructive Pulmonary Disease (COPD) to Assess Patient Handling
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Mundipharma Research
- 10 Jan 2017 New trial record